Cellular changes elicited by 3-day treatments with RST, GGTI, and PA. A–C: RST and GGTI do not affect neuronal viability, whereas PA preconditioning elicits a minor (∼10–15%) decrease in neuronal viability. The vehicle DMSO does not contribute to this effect of PA. For each panel, data are from 2 independent cultures, n = 24–56, 24–72, and 16–64, respectively. *P < 0.05 vs. nontreated controls. D–F: RST, GGTI, and PA all elicit dose-dependent reductions in tetramethylrhodamine ethyl ester (TMRE) fluorescence. The effect of RST is reversed by coapplication with 10 μM mevalonate. For each panel, data are from 4, 2, and 2 independent cultures, n = 24–48, 32–48, and 16–56, respectively. P < 0.05 vs. nontreated controls and all smaller drug doses (*) and vs. RST (†). G–I: RST and PA both significantly decrease neuronal ATP levels. In contrast, GGTI elicits an increase in neuronal ATP. The effect of RST is reversed by coapplication of 10 μM mevalonate. For each panel, data are from 4, 2, and 2 independent cultures, n = 24–32, 32–32, and 32–32, respectively. P < 0.05 vs. nontreated controls and all smaller drug doses (*) and vs. RST (†). J–L: all drugs significantly reduce lactate dehydrogenase (LDH) activity of cultured neurons. The effect of RST is reversed by coapplication of 10 μM mevalonate. For each panel, data are from 3, 2, and 2 independent cultures, n = 8–32, 16–28, and 16–64, respectively. P < 0.05 vs. nontreated controls and all smaller drug doses (*) and vs. RST (†).